Related Experiment Video
Updated: Aug 13, 2026
08:19
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
[Building immune microsphere against tumor necrosis factor-alpha (TNF-alpha)]
Qin Wang1, Xiongfei Wu, Junxia Wang
1Division of Kidney, Southwest Hospital, The Third Military Medical University, Chongqing 400038, China.
Summary
Researchers developed immune microspheres to capture tumor necrosis factor-alpha (TNF-alpha), a key molecule in inflammation. This novel blood purification method offers a simple, economic approach for specific TNF-alpha elimination in future research.
Area of Science:
- Biomaterials Science
- Immunology
- Biotechnology
Context:
- Tumor necrosis factor-alpha (TNF-alpha) plays a significant role in inflammatory diseases.
- Current therapeutic strategies often aim to neutralize TNF-alpha.
- Developing efficient methods for targeted TNF-alpha removal is crucial.
Purpose:
- To construct immune microspheres for the specific elimination of TNF-alpha.
- To establish experimental groundwork for blood purification methods targeting TNF-alpha.
- To optimize the conditions for creating effective TNF-alpha-capturing microspheres.
Summary:
- Recombinant human TNF-alpha monoclonal antibody (rHTNF-alpha McAb) was immobilized onto poly-L-lysine (PLL) coated polystyrene microspheres (PSM).
- Optimal coating conditions were identified as 20°C, pH 9.5, and 60 minutes, with 0.2% glutaraldehyde solution.
- The resulting immune microspheres demonstrated firm binding and suitability as a novel adsorption material.
Impact:
- Provides a simple and economical method for creating TNF-alpha-specific adsorption materials.
- Offers a new approach for blood purification techniques aimed at reducing TNF-alpha levels.
- Potential applications in research and therapeutic strategies for TNF-alpha-related conditions.
More Related Videos
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...